Abstract:Hepatitis B virus (HBV) infections rely on the proper functioning of the viral polymerase enzyme, a specialized reverse transcriptase (RT) with multiple activities. All currently approved antiviral drugs for the treatment of chronic HBV infection, except for interferon, target the RT and belong to the same chemical class - they are all nucleoside analogs. Viral DNA synthesis is carried out by the RT enzyme in several different steps, each with distinct RT conformational requirements. In principle, each stage may be targeted by distinct antiviral drugs. In particular, the HBV RT has the unique ability to initiate viral DNA synthesis using itself as a protein primer in a novel protein priming reaction. In order to help identify RT inhibitors and study their mechanisms of action, a number of experimental systems have been developed, each varying in its ability to dissect the protein priming stage and subsequent stages of viral DNA synthesis at the molecular level. Two of the most effective drugs to date, entecavir and tenofovir, can inhibit both the protein priming and the subsequent DNA elongation stages of HBV DNA synthesis. Interestingly, clevudine, a thymidine analog, can inhibit both protein priming and DNA elongation in a non-competitive manner and without being incorporated into the viral DNA. Thus, a nucleoside RT inhibitor (NRTI) can functionally mimic a non-NRTI (NNRTI) in its inhibition of the HBV RT. Therefore, novel NRTIs as well as NNRTIs may be developed to inhibit the DNA synthesis activity of the HBV RT. Furthermore, additional activities of the RT that are also essential to HBV replication, including specific recognition of the viral RNA and its packaging into viral nucleocapsids, may be exploited for antiviral development. To achieve a more potent inhibition of viral replication and ultimately cure chronic HBV infection, the next generation of anti-HBV therapies will likely need to include NRTIs, NNRTIs, and other agents that target the viral RT as well as other viral and host factors in various combinations. This article forms part of a symposium in Antiviral Research on "An unfinished story: from the discovery of the Australia antigen to the development of new curative therapies for hepatitis B."

Fluorescence-based Biochemical Analysis of Human Hepatitis B Virus Reverse Transcriptase Activity.

Transcomplementation of nucleotide priming and reverse transcription between independently expressed TP and RT domains of the hepatitis B virus reverse transcriptase

A Single Amino Acid in the Reverse Transcriptase Domain of Hepatitis B Virus Affects Virus Replication Efficiency.

Screening and Evaluation of Novel Compounds against Hepatitis B Virus Polymerase Using Highly Purified Reverse Transcriptase Domain

Efficient pyrophosphorolysis by a hepatitis B virus polymerase may be a primer-unblocking mechanism

Hepatitis B virus reverse transcriptase - Target of current antiviral therapy and future drug development

A Putative New Domain Target for Anti‐hepatitis B Virus: Residues Flanking Hepatitis B Virus Reverse Transcriptase Residue 306 (Rtp306)

Quantifying Anti-Hbv Effect of Targeted Ribonuclease by Real-Time Fluorescent PCR.

Relaxing the restricted structural dynamics in the human hepatitis B virus RNA encapsidation signal enables replication initiation in vitro

Characterization of hepatitis B virus reverse transcriptase sequences in Chinese treatment naive patients.

Evaluation of a Novel Fully Automated Real-Time PCR Assay for Hepatitis B Virus DNA Quantification

The Hepatitis B Virus Ribonuclease H Is Sensitive to Inhibitors of the Human Immunodeficiency Virus Ribonuclease H and Integrase Enzymes

The Amino Acid Substitutions Rtp177g and Rtf249a in the Reverse Transcriptase Domain of Hepatitis B Virus Polymerase Reduce the Susceptibility to Tenofovir.

Evolution and phenotypic analysis of rtL229 polymerase mutations within the hepatitis B virus genome

Activity and reverse transcription of hepatitis C virus RNA-dependent RNA polymerase expressed in E.coli

Impacts of HBV Rth55r Polymerase Substitution on Viral Replication and Rtm204i/v Resistance to Nucleoside/nucleotide Antiviral Drugs.

Exploiting New Potential Targets for Anti-Hepatitis B Virus Drugs.

Establishment and application of a novel PCR assay for amplifying the full-length reverse transcriptase gene region of genotypes A～D of hepatitis B virus

In vitro reconstitution of functional hepadnavirus reverse transcriptase with cellular chaperone proteins

Non-nucleoside hepatitis B virus polymerase inhibitors identified by an in vitro polymerase elongation assay

Chaperones activate hepadnavirus reverse transcriptase by transiently exposing a C-proximal region in the terminal protein domain that contributes to epsilon RNA binding